Biological engineering

TerraSafe Materials and Penn State Announce Licensing Agreement to Commercialize Breakthrough Material Technologies

Retrieved on: 
Tuesday, February 27, 2024

TerraSafe is launching its first rural Research & Development facility at the Penn State Innovation Park, where the Company plans to run analytic testing for new material technologies in development.

Key Points: 
  • TerraSafe is launching its first rural Research & Development facility at the Penn State Innovation Park, where the Company plans to run analytic testing for new material technologies in development.
  • TerraSafe is leveraging intellectual property created by researchers at the Pennsylvania State University (“PSU”) in the biomaterials space.
  • “The support that this ecosystem can bring to startups like TerraSafe is why we located our first R&D center in State College.
  • The collaboration between TerraSafe and Penn State marks a major milestone of its core mission to build and grow companies throughout the rural United States.

Universal Display Corporation Announces the Appointment of New Board Members

Retrieved on: 
Thursday, March 7, 2024

Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company’s Board of Directors, effective March 4, 2024.

Key Points: 
  • Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company’s Board of Directors, effective March 4, 2024.
  • The addition of these new directors expands UDC’s Board to ten members.
  • “I am pleased to welcome Nigel and Joan to the Board,” said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board.
  • “Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board.

Flinn Foundation Names Leadership of Arizona’s Statewide Bioscience Committee

Retrieved on: 
Tuesday, February 27, 2024

The committee, administered by the Flinn Foundation, is the statewide leadership group responsible for overseeing Arizona’s Bioscience Roadmap, the long-term strategic plan to guide the growth and development of the state’s bioscience sector.

Key Points: 
  • The committee, administered by the Flinn Foundation, is the statewide leadership group responsible for overseeing Arizona’s Bioscience Roadmap, the long-term strategic plan to guide the growth and development of the state’s bioscience sector.
  • Barton, who became a committee member in 2013, will be in a committee leadership position for the first time.
  • Over the next 18 months, the committee’s guidance will be critical in the Flinn Foundation’s planned update to Arizona’s Bioscience Roadmap—the first since 2014.
  • Carter joins a distinguished group of community and bioscience leaders who have led the committee since its inception in 2002.

Comprehensive Study from 50 Top Scientists Details Five Cutting-edge Advances in Biomedical Engineering and Their Applications in Medicine

Retrieved on: 
Thursday, February 22, 2024

Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.

Key Points: 
  • Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.
  • By focusing on these five areas, the consortium has laid out a roadmap for future research and funding.
  • Advanced technologies, such as wearable sensors and digital twins, can provide the basis of a solution to this challenge.
  • Despite the rapid advances in genomics in the past few decades, there are obstacles remaining in our ability to engineer genomic DNA.

AMDI Receives a $5.3M NIH RADx® Tech Award to Finalize Development of Its 10 Minute RT-PCR Point-of-Care System and Respiratory Panel

Retrieved on: 
Wednesday, February 28, 2024

The funding will also be used to complete the first test panel for the Fast PCR system, targeting detection of multiple respiratory viruses: Influenza A and B, respiratory syncytial virus (RSV), and SARS-CoV-2.

Key Points: 
  • The funding will also be used to complete the first test panel for the Fast PCR system, targeting detection of multiple respiratory viruses: Influenza A and B, respiratory syncytial virus (RSV), and SARS-CoV-2.
  • The RADx Tech program was created to speed innovation and address critical public health challenges like the COVID-19 pandemic.
  • "AMDI is grateful for the recognition by the NIBIB for a second award that gives us the opportunity to complete the development of the Fast PCR System," said David Okrongly, CEO of AMDI.
  • The HBH technology removes the time constraints and costs associated with traditional sample prep", said Regis Peytavi, CTO of AMDI.

Matter Neuroscience Secures $26M in Funding to Cure Unhappiness

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Matter Neuroscience, the company working to unlock a deeper understanding of happiness and well-being by providing people with personalized insights into their brain chemistry emerges from stealth mode today. Matter announced it has received $26 million in funding, initial funding seeded by Polaris Partners and a more recent round co-led by ARCH Venture Partners, Polaris Partners, and Exor Ventures, and joined by Collaborative Fund and others. With this backing, Matter will bolster its efforts to pioneer solutions that address the unhappiness epidemic by transforming our understanding and management of mental well-being.

Key Points: 
  • With this backing, Matter will bolster its efforts to pioneer solutions that address the unhappiness epidemic by transforming our understanding and management of mental well-being.
  • Together with its collaboration partners, Matter Neuroscience will initiate three more clinical studies in 2024.
  • Matter also offers users access to educational materials and a lecture series on the neuroscience of happiness.
  • Matter Neuroscience was co-founded in 2019 with Ben Goldhirsh of GOOD Worldwide and the Goldhirsh Foundation, and Chris Shiflett of Faculty and Brooklyn Beta.

Elevage Medical Technologies Continues Expansion of Investment Team and Board

Retrieved on: 
Tuesday, February 27, 2024

AUSTIN, Texas, Feb. 27, 2024 /PRNewswire/ -- Elevage Medical Technologies ("Elevage"), a portfolio company of Patient Square Capital, dedicated to supporting growth-stage medical device and medical technology companies, today announced key additions to the investment team and board. Vice-Presidents Suchira Sharma and Peter Tortora join the Elevage investment team, along with Dr. Josh Makower, a Senior Advisor to Patient Square and Elevage, who will also join the Elevage Board of Directors.

Key Points: 
  • hires –
    AUSTIN, Texas, Feb. 27, 2024 /PRNewswire/ -- Elevage Medical Technologies ("Elevage"), a portfolio company of Patient Square Capital , dedicated to supporting growth-stage medical device and medical technology companies, today announced key additions to the investment team and board.
  • Vice-Presidents Suchira Sharma and Peter Tortora join the Elevage investment team, along with Dr. Josh Makower, a Senior Advisor to Patient Square and Elevage, who will also join the Elevage Board of Directors.
  • Dr. Evan Melrose, CEO of Elevage Medical, said, "We are thrilled with these three key additions to the Elevage team.
  • Dr. Makower is also the Founder & Executive Chairman of ExploraMed, a medical device incubator that has created eleven companies since 1995.

EnLiSense CCM Advances Validation of Real-Time IBD Inflammatory Biomarker Monitoring with Two Recent Peer-Reviewed Longitudinal Studies

Retrieved on: 
Thursday, February 15, 2024

Our innovative IBD Aware device offers the first solution for continuous, non-invasive monitoring of IBD through the power of sweat-sensing technology.

Key Points: 
  • Our innovative IBD Aware device offers the first solution for continuous, non-invasive monitoring of IBD through the power of sweat-sensing technology.
  • EnLiSense's journey reaches a significant milestone with over half a million human biomarker readings, underscoring the extensive validation of our technology.
  • These readings provide crucial data points, enhancing the precision and trustworthiness of inflammatory biomarker monitoring.
  • The studies involved measuring inflammation markers CRP, TNF-α, and IL-6 in subjects' blood and sweat continuously in subjects with and without IBD.

Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation

Retrieved on: 
Thursday, February 1, 2024

Edinburgh, Scotland, 1 February 2024 – Cumulus Oncology (a biotech creation company) today proudly unveils the inauguration of GIO Therapeutics AG, based in Basel, Switzerland.

Key Points: 
  • Edinburgh, Scotland, 1 February 2024 – Cumulus Oncology (a biotech creation company) today proudly unveils the inauguration of GIO Therapeutics AG, based in Basel, Switzerland.
  • This newly established biotech company specialises in the development of pharmaceuticals targeting G protein-coupled receptors (GPCR).
  • Heading GIO Therapeutics is Dr Xavier Leroy who has been appointed as Chief Executive Officer.
  • Dr Xavier Leroy, CEO of GIO Therapeutics commented: “While GPCRs are well-known drug targets, their potential in cancer therapeutics is currently underutilised.

Maxim Biomedical, Inc. Secures Second NIH RADx Tech High Performance Award for Continued Development of At-Home FiarFly™ Reader and COVID-19 & Flu A/B Rapid Test

Retrieved on: 
Thursday, February 1, 2024

ROCKVILLE, Md., Feb. 1, 2024 /PRNewswire/ -- MaximBio, a leading innovator in next-generation healthcare diagnostic technologies, is pleased to announce that it has been granted a second follow-on award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program for the continued development of its revolutionary FiarFly™ reader and COVID-19 & Flu A/B multiplex test.

Key Points: 
  • ROCKVILLE, Md., Feb. 1, 2024 /PRNewswire/ -- MaximBio, a leading innovator in next-generation healthcare diagnostic technologies, is pleased to announce that it has been granted a second follow-on award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program for the continued development of its revolutionary FiarFly™ reader and COVID-19 & Flu A/B multiplex test.
  • This additional Phase 2 award, totaling approximately $4.4 million, will be used to accelerate the development of the FiarFly™ reader and COVID-19 & Flu A/B multiplex test and quickly prepare for clinical trials targeting this influenza season.
  • "We are honored to receive another award from the NIH RADx Tech program and continue to build upon our successful programs with the NIH," said Jonathan Maa, Chief Operating Officer at MaximBio.
  • This award underscores MaximBio's commitment to advancing cutting-edge diagnostic solutions to address the ongoing challenges posed by multiple infectious diseases and increasing access to high-quality, rapid testing solutions.